Shandong Sito Bio-technology Co Ltd (300583) - Total Assets
Based on the latest financial reports, Shandong Sito Bio-technology Co Ltd (300583) holds total assets worth CN¥2.87 Billion CNY (≈ $419.40 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 300583 net assets for net asset value and shareholders' equity analysis.
Shandong Sito Bio-technology Co Ltd - Total Assets Trend (2012–2024)
This chart illustrates how Shandong Sito Bio-technology Co Ltd's total assets have evolved over time, based on quarterly financial data.
Shandong Sito Bio-technology Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Shandong Sito Bio-technology Co Ltd's total assets of CN¥2.87 Billion consist of 42.5% current assets and 57.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.5% |
| Accounts Receivable | CN¥349.75 Million | 11.6% |
| Inventory | CN¥644.88 Million | 21.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥189.15 Million | 6.3% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Shandong Sito Bio-technology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Shandong Sito Bio-technology Co Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shandong Sito Bio-technology Co Ltd's current assets represent 42.5% of total assets in 2024, a decrease from 52.7% in 2012.
- Cash Position: Cash and equivalents constituted 8.5% of total assets in 2024, up from 0.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, a decrease from 19.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 21.3% of total assets.
Shandong Sito Bio-technology Co Ltd Competitors by Total Assets
Key competitors of Shandong Sito Bio-technology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Shandong Sito Bio-technology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.21 | 1.38 | 1.21 |
| Quick Ratio | 0.71 | 0.67 | 0.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥207.07 Million | CN¥369.73 Million | CN¥201.38 Million |
Shandong Sito Bio-technology Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shandong Sito Bio-technology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.60 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | -6.6% |
| Total Assets | CN¥3.03 Billion |
| Market Capitalization | $419.72 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shandong Sito Bio-technology Co Ltd's assets below their book value (0.14x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shandong Sito Bio-technology Co Ltd's assets decreased by 6.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shandong Sito Bio-technology Co Ltd (2012–2024)
The table below shows the annual total assets of Shandong Sito Bio-technology Co Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.03 Billion ≈ $442.77 Million |
-6.62% |
| 2023-12-31 | CN¥3.24 Billion ≈ $474.15 Million |
+8.18% |
| 2022-12-31 | CN¥3.00 Billion ≈ $438.28 Million |
+0.86% |
| 2021-12-31 | CN¥2.97 Billion ≈ $434.56 Million |
+4.52% |
| 2020-12-31 | CN¥2.84 Billion ≈ $415.77 Million |
-4.89% |
| 2019-12-31 | CN¥2.99 Billion ≈ $437.13 Million |
+15.14% |
| 2018-12-31 | CN¥2.59 Billion ≈ $379.65 Million |
+28.15% |
| 2017-12-31 | CN¥2.02 Billion ≈ $296.26 Million |
+116.25% |
| 2016-12-31 | CN¥936.23 Million ≈ $137.00 Million |
+11.68% |
| 2015-12-31 | CN¥838.28 Million ≈ $122.67 Million |
+65.30% |
| 2014-12-31 | CN¥507.11 Million ≈ $74.21 Million |
+140.73% |
| 2013-12-31 | CN¥210.66 Million ≈ $30.83 Million |
+251.20% |
| 2012-12-31 | CN¥59.98 Million ≈ $8.78 Million |
-- |
About Shandong Sito Bio-technology Co Ltd
Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, ethylene deltenone, 16ß and 16a me… Read more